metaEvidence - overview


			DCR
ovarian cancer (OC) ovarian cancer (OC)
metastatic/advanced OC (mOC) - 1st line (L1) metastatic/advanced OC (mOC) - 1st line (L1)
mOC - L1 - all population metastatic/advanced OC (mOC) - 1st line (L1) mOC - L1 - all population
mOC - L1 - PDL1 positive metastatic/advanced OC (mOC) - 1st line (L1) mOC - L1 - PDL1 positive
metastatic/advanced OC (mOC) - 2nd line (L2) metastatic/advanced OC (mOC) - 2nd line (L2)
versus pegylated liposomal doxorubicin
	avelumab alone vs. pegylated liposomal doxorubicin	1	1684 [706; 2661] /10000 93/188 vs. 62/190
	avelumab plus pegylated liposomal doxorubicin vs. pegylated liposomal doxorubicin	1	2482 [1510; 3453] /10000 108/188 vs. 62/190
metastatic/advanced OC (mOC) - maintenance (M) metastatic/advanced OC (mOC) - maintenance (M)